Sánchez-De la Rosa R, Sabater E, Casado M A
Departamento Médico, Teva Pharma SLU, Alcobendas, Madrid, España.
Rev Neurol. 2011 Aug 1;53(3):129-38.
To assess the budget impact of the treatment for relapsing remitting multiple sclerosis (RRMS), interferons, and glatiramer acetate, from the National Health System perspective in Spain.
A budget impact model was designed to compare the cost of RRMS treatment in different settings, using a five year time-horizon, considering different percentages of administration of each medication. A reference setting o base case using all the available first line treatments (interferons and glatiramer acetate) was compared with five alternatives scenarios excluding each one of these treatments. The cost analysis (euros, year 2010) includes direct medical resources (drugs, administration, visits, disease management, diagnostic tests). Unitary cost data was obtained from the health costs database e-Salud and drugs catalogue.
Considering a cohort of 22 255 patients with RRMS, the mean global budget impact per year would be 260 775 470 euros in the base case. The setting that excluded glatiramer acetate increases the budget impact in a 3.23% (372 euros per patient per year). Pharmacological costs were the key drivers of total cost (90%).
The use of glatiramer acetate in the first-line-treatment of RRMS patients is a cost-saving strategy, which may decrease the budget impact from the National Health System perspective in Spain.
从西班牙国家卫生系统的角度评估复发缓解型多发性硬化症（RRMS）治疗药物干扰素和醋酸格拉替雷的预算影响。
设计了一个预算影响模型，以五年时间跨度比较不同情况下RRMS治疗的成本，考虑每种药物不同的给药百分比。将使用所有可用一线治疗（干扰素和醋酸格拉替雷）的参考情况或基础病例与排除这些治疗中每一种的五个替代方案进行比较。成本分析（2010年欧元）包括直接医疗资源（药物、给药、就诊、疾病管理、诊断测试）。单位成本数据来自卫生成本数据库e-Salud和药品目录。
考虑到22255名RRMS患者队列，基础病例中每年的平均总体预算影响为260775470欧元。排除醋酸格拉替雷的情况使预算影响增加3.23%（每位患者每年372欧元）。药物成本是总成本的主要驱动因素（90%）。
在RRMS患者的一线治疗中使用醋酸格拉替雷是一种节省成本的策略，从西班牙国家卫生系统的角度来看，这可能会降低预算影响。
